LOGO
LOGO

Natera Targets $2Bln Revenue In 2025

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us
mananddartboards 08082025 lt

There appears to be no slowing down for Natera Inc. (NTRA), with the diagnostics company once again revising up its revenue outlook for 2025.

The company offers cell-free DNA testing, with a focus on oncology, women's health, and organ health.

Cell-free DNA, or cfDNA in short, refers to small fragments of DNA that are released from normal cells and diseased cells into the blood. The cell-free DNA testing is of use in identifying genomic variants associated with a hereditary or genetic disorder and for the detection and characterization of some cancers, and to monitor cancer therapy.

Subscribe to continue reading the article.
This article is available exclusively to RTT Biotech Investor and Intelligent Investor subscribers. Subscribe with a RTTNews subscription.
Start Free Trial
FREE 7-Day Trial - No Payment Required
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Global Economics Weekly Update -June 15 - June 19, 2026

June 19, 2026 16:46 ET
Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.